Evidence map›Paper›PMID 42026389›Full record

ArticleAAPS PharmSciTech2026

Development of a New Aerosol Delivery System for Administering Aerosol Surfactant Therapy to Preterm Infants Through a Laryngeal Mask Airway.

Sarah C Strickler, Caleb J Dalton, Felicia G Hall, Dale R Farkas, Mohammad A M Momin, Robert M DiBlasi, Michael Hindle, P Worth Longest

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sarah C StricklerDepartment of Mechanical and Nuclear Engineering, Virginia Commonwealth University, 401 West Main Street, Richmond, Virginia, P.O. Box 843015, 23284-3015, USA.ORCID http://orcid.org/0000-0003-2443-5570
Caleb J DaltonDepartment of Pharmaceutics, Virginia Commonwealth University, 410 N 12 Street, Richmond, Virginia, PO Box 980533, 23298, USA.ORCID http://orcid.org/0009-0007-4187-3026
Felicia G HallDepartment of Pharmaceutics, Virginia Commonwealth University, 410 N 12 Street, Richmond, Virginia, PO Box 980533, 23298, USA.ORCID http://orcid.org/0009-0007-0467-1740
Dale R FarkasDepartment of Mechanical and Nuclear Engineering, Virginia Commonwealth University, 401 West Main Street, Richmond, Virginia, P.O. Box 843015, 23284-3015, USA.ORCID http://orcid.org/0000-0001-7295-7555
Mohammad A M MominDepartment of Pharmaceutics, Virginia Commonwealth University, 410 N 12 Street, Richmond, Virginia, PO Box 980533, 23298, USA.ORCID http://orcid.org/0000-0003-1463-0719
Robert M DiBlasiCenter for Respiratory Biology and Therapeutics, Seattle Children's Research Institute, 1900 Ninth Avenue, Seattle, Washington, 98101, USA.ORCID http://orcid.org/0000-0002-9206-7346
Michael HindleDepartment of Pharmaceutics, Virginia Commonwealth University, 410 N 12 Street, Richmond, Virginia, PO Box 980533, 23298, USA.ORCID http://orcid.org/0000-0002-1025-1183
P Worth LongestDepartment of Mechanical and Nuclear Engineering, Virginia Commonwealth University, 401 West Main Street, Richmond, Virginia, P.O. Box 843015, 23284-3015, USA. pwlongest@vcu.edu.ORCID http://orcid.org/0000-0003-4939-5691

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, aerosol surfactant therapy administered through a laryngeal mask airway (LMA) was investigated as an alternative to the more invasive approach of surfactant liquid bolus instillation, which carries significant risks to infants with respiratory distress syndrome. Combining a recently developed synthetic lung surfactant excipient enhanced growth (SLS-EEG) dry powder formulation with a novel LMA aerosol delivery system (LMA-ADS) was intended to avoid the side effects associated with current liquid bolus therapies. A new patient connection system (PCS) was developed for introducing the aerosol from an infant air-jet DPI into the LMA. Using in vitro benchtop studies with a 1.5 kg preterm infant extrathoracic model, the effectiveness of a co-flow (CF) strategy was investigated for improving lung delivery efficiencies of the aerosol. Next, different tubing sizes and aerosolization parameters were explored using laser diffraction to quantify their effects on aerosol size distribution metrics, and insights gained were implemented to develop four PCS designs. The best-performing PCS was tested with a realistic pulmonary mechanics (PM) model. Large-diameter tubing (> 1 mm diameter) was shown to produce large aerosol size increases that could be minimized with smaller-diameter tubing. Following integration of 0.8 mm inner diameter tubing, all PCS designs were capable of at least ~ 24% lung delivery efficiency (based on loaded dose) with the best-performing PCS reaching ~ 29%, which represented a > 1.7-fold improvement from baseline. PM simulations confirmed safe delivery pressures with only minor reductions in aerosol transmission. Therefore, the LMA-ADS could be a promising alternative for effective aerosol surfactant therapies.

Indexed as

Drug Delivery SystemsLaryngeal MasksPulmonary SurfactantsAdministration, InhalationAerosolsChemistry, PharmaceuticalExcipientsHumansInfant, NewbornInfant, PrematureParticle SizeRespiratory Distress Syndrome, NewbornAerosolsExcipientsPulmonary Surfactantsactive dry powder inhalerair-jet dry powder inhalerdry powder aerosolinfant aerosol deliverylaryngeal mask airway aerosol delivery

Identifiers

PMID42026389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.